Back to Search Start Over

Susceptibility to infections and adaptive immunity in adults with heart failure.

Authors :
Salzer U
Müller A
Zhou Q
Nieters A
Grundmann S
Wehr C
Source :
ESC heart failure [ESC Heart Fail] 2022 Apr; Vol. 9 (2), pp. 1195-1205. Date of Electronic Publication: 2022 Jan 14.
Publication Year :
2022

Abstract

Aims: Heart failure (HF) is a systemic inflammatory disorder with infections being an important cause of morbidity and mortality. We asked if HF patients have a higher susceptibility to infections compared with the general population and if a subtle secondary immunodeficiency facilitates infectious complications.<br />Methods and Results: In a cohort of 92 patients with HF with reduced ejection fraction, we analysed recirculating lymphocyte subpopulations, serum immunoglobulin levels, and specific antibody titres against pneumococcal antigens. We quantified susceptibility to infections of the respiratory tract with a validated questionnaire and compared it to the general population. Susceptibility to infections of the respiratory tract was comparable in HF patients and the general population. Hypogammaglobulinaemia was present in 16% of HF patients, but anti-pneumococcal titres showed no evidence of specific secondary antibody deficiency. Relative lymphopaenia in our HF cohort was due to B lymphocytopenia with a relative reduction in naive B-cells and expansion of memory B-cells while CD4+ and CD8+ T-lymphocytes as well as NK-cell counts were comparable between HF and healthy donors. The intake of the angiotensin receptor neprilysin (CD10) inhibitor (ARNI) sacubitril/valsartan was associated with increased B-lymphocyte counts, possibly by an increased output of CD10+ transitional B lymphocytes from the bone marrow.<br />Conclusion: Despite a reduction of B lymphocytes in HF and mild hypogammaglobulinaemia, patients showed no evidence of secondary immunodeficiency or increased susceptibility to infections. The relevance of B-cell lymphopenia in HF patients and modulation of B-cell counts under ARNI treatment remains to be investigated.<br /> (© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Details

Language :
English
ISSN :
2055-5822
Volume :
9
Issue :
2
Database :
MEDLINE
Journal :
ESC heart failure
Publication Type :
Academic Journal
Accession number :
35032103
Full Text :
https://doi.org/10.1002/ehf2.13793